Cargando…

Market Failure and the Poverty of New Drugs in Maternal Health

A new survey finds that only 17 drugs are under active development for maternal health indications, which is less than 3% of the pipeline in cardiovascular health (660 drugs).

Detalles Bibliográficos
Autores principales:	Fisk, Nicholas M, Atun, Rifat
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2008
Materias:	Policy Forum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211556/ https://www.ncbi.nlm.nih.gov/pubmed/18215109 http://dx.doi.org/10.1371/journal.pmed.0050022

Ejemplares similares

Financing Essential HIV Services: A New Economic Agenda
por: Vassall, Anna, et al.
Publicado: (2013)

Evidence-based policymaking when evidence is incomplete: The case of HIV programme integration
por: Hontelez, Jan A. C., et al.
Publicado: (2021)

Guidance for Evidence-Informed Policies about Health Systems: Linking Guidance Development to Policy Development
por: Lavis, John N., et al.
Publicado: (2012)

Harnessing Poverty Alleviation to Reduce the Stigma of HIV in Sub-Saharan Africa
por: Tsai, Alexander C., et al.
Publicado: (2013)

Guidance for Evidence-Informed Policies about Health Systems: Rationale for and Challenges of Guidance Development
por: Bosch-Capblanch, Xavier, et al.
Publicado: (2012)

Grand Challenges: Integrating Maternal Mental Health into Maternal and Child Health Programmes
por: Rahman, Atif, et al.
Publicado: (2013)

Regulating the Market in Human Research Participants
por: Lemmens, Trudo, et al.
Publicado: (2006)

Direct-to-consumer Marketing to People with Hemophilia
por: Kucab, Philip, et al.
Publicado: (2016)

Examining the “Urban Advantage” in Maternal Health Care in Developing Countries
por: Matthews, Zoë, et al.
Publicado: (2010)

New era of drug innovation in China
por: Ye, Xuan, et al.
Publicado: (2019)

Financing Maternal and Child Health—What Are the Limitations in Estimating Donor Flows and Resource Needs?
por: Schäferhoff, Marco, et al.
Publicado: (2010)

New Approaches to Filling the Gap in Tuberculosis Drug Discovery
por: Casenghi, Martina, et al.
Publicado: (2007)

A New Approach to Psychiatric Drug Approval in Europe
por: Barbui, Corrado, et al.
Publicado: (2013)

Registering New Drugs for Low-Income Countries: The African Challenge
por: Moran, Mary, et al.
Publicado: (2011)

From Joint Thinking to Joint Action: A Call to Action on Improving Water, Sanitation, and Hygiene for Maternal and Newborn Health
por: Velleman, Yael, et al.
Publicado: (2014)

Improving Men’s Participation in Preventing Mother-to-Child Transmission of HIV as a Maternal, Neonatal, and Child Health Priority in South Africa
por: van den Berg, Wessel, et al.
Publicado: (2015)

The New International Health Regulations and the Federalism Dilemma
por: Wilson, Kumanan, et al.
Publicado: (2006)

Will Spam Overwhelm Our Defenses? Evaluating Offerings for Drugs and Natural Health Products
por: Gernburd, Peter, et al.
Publicado: (2007)

The Global Threat of Counterfeit Drugs: Why Industry and Governments Must Communicate the Dangers
por: Cockburn, Robert, et al.
Publicado: (2005)

The Community As the Patient in Malaria-Endemic Areas: Preempting Drug Resistance with Multiple First-Line Therapies
por: Boni, Maciej F., et al.
Publicado: (2016)

Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria
por: Borrmann, Steffen, et al.
Publicado: (2008)

New Signal Functions to Measure the Ability of Health Facilities to Provide Routine and Emergency Newborn Care
por: Gabrysch, Sabine, et al.
Publicado: (2012)

Evolution of drug regulations and regulatory innovation for anticancer drugs in China
por: Liu, Yang, et al.
Publicado: (2022)

Social Entrepreneurship for Sexual Health (SESH): A New Approach for Enabling Delivery of Sexual Health Services among Most-at-Risk Populations
por: Tucker, Joseph D., et al.
Publicado: (2012)

Educating a New Generation of Doctors to Improve the Health of Populations in Low- and Middle-Income Countries
por: Celletti, Francesca, et al.
Publicado: (2011)

The Great Failure of Malaria Control in Africa: A District Perspective from Burkina Faso
por: Kouyaté, Bocar, et al.
Publicado: (2007)

A Public Health Framework for Legalized Retail Marijuana Based on the US Experience: Avoiding a New Tobacco Industry
por: Barry, Rachel Ann, et al.
Publicado: (2016)

Recommendations on data sharing in HIV drug resistance research
por: Inzaule, Seth C., et al.
Publicado: (2023)

Cholinesterase Inhibitors: Drugs Looking for a Disease?
por: Maggini, Marina, et al.
Publicado: (2006)

Global Pharmacovigilance for Antiretroviral Drugs: Overcoming Contrasting Priorities
por: Bakare, Nyasha, et al.
Publicado: (2011)

A Prescription for Improving Drug Formulary Decision Making
por: Schiff, Gordon D., et al.
Publicado: (2012)

Open Peer Commentary to “Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019”
por: Sabbagh, Marwan Noel, et al.
Publicado: (2020)

Criteria for Drugs Used in Pre-Exposure Prophylaxis Trials against HIV Infection
por: Derdelinckx, Inge, et al.
Publicado: (2006)

The Inadequate Treatment of Pain: Collateral Damage from the War on Drugs
por: Nickerson, Jason W., et al.
Publicado: (2012)

Botanical drug clinical trial: Common issues and future options
por: Sun, Yu, et al.
Publicado: (2021)

Following the Script: How Drug Reps Make Friends and Influence Doctors
por: Fugh-Berman, Adriane, et al.
Publicado: (2007)

Building Clinical Trials Capacity for Tuberculosis Drugs in High-Burden Countries
por: Schluger, Neil, et al.
Publicado: (2007)

Paying Physicians to Prescribe Generic Drugs and Follow-On Biologics in the United States
por: Sarpatwari, Ameet, et al.
Publicado: (2015)

Water Supply and Health
por: Hunter, Paul R., et al.
Publicado: (2010)

Disease Mongering in Drug Promotion: Do Governments Have a Regulatory Role?
por: Mintzes, Barbara
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_chnftlr06ukju28oac4qod6qfq